A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Study ID
NCT02753127

Study type
Interventional

Study phase
Phase 3

Study status
Completed

Trial Acronym

CanStem303C

Trial Summary

This is an international multi-center, prospective, open-label, randomized, adaptive design phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly FOLFIRI in patients with previously treated metastatic colorectal cancer (CRC).

More informations

Trial Starting Date

Jun 30,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

1253